Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Burn Healing and Analgesia With Propranolol (BURN HELP)

This study has been completed.
Information provided by (Responsible Party):
Samuel McLean, MD, University of North Carolina, Chapel Hill Identifier:
First received: July 6, 2009
Last updated: October 7, 2014
Last verified: October 2014
The purpose of this study is to investigate the ability of propranolol to decrease pain and improve recovery in burn patients with a common genotype.

Condition Intervention Phase
Drug: Propranolol
Drug: Placebo
Drug: Propanolol
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The BURN HELP Trial: BURN Healing and AnaLgesia With Propranolol

Resource links provided by NLM:

Further study details as provided by University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • Overall Pain Trajectory Slopes [ Time Frame: Study days 5, 7, 10, 13, 17 and 19 ]
    Overall pain trajectory slopes by treatment group, where linear mixed modeling was used to combine pain measurements (waking, worst, and least pain) assessed on primary outcome days into an overall pain score. Pain was assessed using a 0-10 numeric rating scale (NRS). A lower score on the NRS indicated less pain and a higher score was indicative of worse pain.

Secondary Outcome Measures:
  • Sleep Quality [ Time Frame: Study days 5, 7, 10, 13, 17, and 19, study week 6, study months 3 and 6 ]
  • Itch Symptoms [ Time Frame: Study days 5, 7, 10, 13, 17, and 19, study week 6, study months 3 and 6 ]
  • Anxiety Symptoms [ Time Frame: Study days 5, 7, 10, 13, 17, and 19, study week 6, study months 3 and 6 ]

Enrollment: 45
Study Start Date: July 2009
Study Completion Date: June 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Sugar pill Drug: Placebo
sugar pill
Other Name: Sugar pill
Experimental: Propranolol, Propanolol ER Drug: Propranolol
40 mg
Other Names:
  • Inderal
  • Innopran
Drug: Propanolol
120 mg twice per day
Other Names:
  • Inderal
  • Innopran


Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Thermal burn
  • Greater than or equal to 18 years of age
  • Less than 60 years of age
  • Able to speak and read English

Exclusion Criteria:

  • Intubated
  • Clinically unstable
  • Other substantial comorbid injury (e.g. long bone fracture)
  • Heart block greater than first degree (EKG)
  • History of coronary artery disease
  • History of congestive heart failure
  • Asthma (within past 10 years, induced by a beta-blocker, or receiving current treatment)
  • Pregnant
  • Prisoner
  • Psychotic, suicidal, or homicidal
  • Diabetic
  • Hepatic failure (acute or chronic)
  • Renal failure (acute or chronic)
  • History of hyperthyroidism unless taking synthroid or other thyroid hormone replacement
  • Exceeds daily acceptable chronic opioid use prior to burn
  • Interacting medication
  • Received propranolol within the last 6 months
  • Multiple severe allergic reactions
  • On daily methylphenidate or similar stimulant medication
  • Unwilling to use medically acceptable birth control (if childbearing potential)
  • Breastfeeding
  • Severe peripheral vascular disease or vasospastic disorder
  • Bradycardia that in the opinion of the investigator would constitute too great a risk when considered in the context of the patient's medical comorbidities and health history
  • Other criteria that in investigator's opinion makes participant poor candidate for the trial
  • Cancer (except basal cell cancer)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00934947

United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20011
United States, North Carolina
North Carolina Jaycee Burn Center
Chapel Hill, North Carolina, United States, 27514
Wake Forest University Baptist
Wake Forest, North Carolina, United States, 27587
United States, Pennsylvania
Crozer Chester Medical Center
Upland, Pennsylvania, United States, 19102
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Principal Investigator: Samuel McLean, MD, MPh University of North Carolina, Department of Anesthesiology
  More Information

Additional Information:
Responsible Party: Samuel McLean, MD, Principle Investigator, University of North Carolina, Chapel Hill Identifier: NCT00934947     History of Changes
Other Study ID Numbers: 09-0681
Study First Received: July 6, 2009
Results First Received: May 7, 2012
Last Updated: October 7, 2014

Keywords provided by University of North Carolina, Chapel Hill:

Additional relevant MeSH terms:
Wounds and Injuries
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents processed this record on May 22, 2017